The Supreme Court of India has sought a response from Snapdeal and its directors in a case involving the alleged online sale of a prescription-only medicine without a valid licence or a doctor’s prescription. The matter arose from a petition filed by the Karnataka government challenging a Karnataka High Court order that had quashed criminal proceedings against the e-commerce marketplace and its officials. The case is expected to clarify the extent of legal responsibility online marketplaces bear when third-party sellers allegedly violate drug safety regulations.
The dispute centers on the alleged sale of Suhagra-100, a Schedule H prescription medicine containing sildenafil, through Snapdeal’s platform. Karnataka authorities claim the medicine was sold by an allegedly unlicensed seller without requiring a valid prescription, raising concerns about compliance with the Drugs and Cosmetics Act, 1940 and public health safeguards.
Supreme Court Issues Notice to Snapdeal
A Bench comprising Justices Ahsanuddin Amanullah and R. Mahadevan issued notices to Snapdeal while hearing the Karnataka government’s Special Leave Petition (SLP) against the High Court’s decision.
The Court has sought replies on:
- The Special Leave Petition filed by Karnataka.
- The application seeking condonation of delay.
- The challenge to the High Court’s order quashing criminal proceedings.
The matter has been listed for further hearing on August 10.
Case Snapshot
| Item | Details |
|---|---|
| Court | Supreme Court of India |
| Petitioner | Government of Karnataka |
| Respondents | Snapdeal and its directors |
| Product involved | Suhagra-100 (Schedule H medicine) |
| Current stage | Notice issued; reply sought from Snapdeal |
| Next hearing | August 10 |
Background of the Dispute
The case dates back to allegations that a Schedule H prescription drug was sold through Snapdeal’s marketplace without complying with statutory requirements.
According to Karnataka’s Drugs Control Department:
- The medicine was allegedly sold without a doctor’s prescription.
- The seller allegedly lacked the required licence.
- The transaction violated provisions of the Drugs and Cosmetics Act.
Criminal proceedings were initiated against Snapdeal, its co-founders, and others. However, the Karnataka High Court later quashed those proceedings, prompting the state government to approach the Supreme Court.
Key Legal Questions
The Supreme Court is expected to examine several important issues affecting India’s e-commerce sector.
These include:
- Whether online marketplaces can be held criminally liable for listings by third-party sellers.
- Whether marketplace operators can rely on “safe harbour” protections under the Information Technology Act when public health laws are allegedly violated.
- The extent of due diligence required before allowing prescription medicines to be sold online.
- Whether digital platforms must implement stronger verification mechanisms for regulated products.
Issues Before the Court
| Legal Question | Why It Matters |
|---|---|
| Marketplace liability | Determines responsibility for third-party sellers |
| Safe harbour protection | Clarifies limits of IT Act immunity |
| Prescription verification | Strengthens safeguards for regulated medicines |
| Seller compliance | Defines due diligence obligations for e-commerce platforms |
Potential Impact on India’s E-Commerce Industry
The outcome of the case could influence how online marketplaces handle the sale of regulated products, particularly medicines.
If the Court imposes stricter obligations, e-commerce platforms may need to:
- Enhance seller verification procedures.
- Strengthen prescription validation systems.
- Improve monitoring of regulated product listings.
- Introduce additional compliance checks before transactions are completed.
The ruling could also provide legal clarity for other online marketplaces dealing in pharmaceuticals and healthcare products.
Looking Ahead
The Supreme Court’s decision to seek Snapdeal’s response marks the beginning of what could become a landmark case on the liability of online marketplaces for the sale of regulated products. While the Court has not expressed any view on the merits of the allegations, its eventual ruling could define how far e-commerce platforms must go to ensure compliance with India’s drug safety laws when facilitating third-party sales.
For the broader e-commerce industry, the case could establish important legal precedents on the balance between intermediary protections under the Information Technology Act and obligations under sector-specific laws such as the Drugs and Cosmetics Act. Businesses, regulators, and consumers will be watching closely as the Supreme Court considers the scope of platform accountability in India’s rapidly growing digital marketplace.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
